Report of Foreign Issuer (6-k)
April 05 2017 - 8:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant
to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of April 2017
001-36345
(Commission File Number)
GALMED PHARMACEUTICALS LTD.
(Exact name of Registrant as specified in
its charter)
16 Tiomkin St.
Tel Aviv 6578317, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Attached
hereto and incorporated herein by reference is a press release, dated April 5, 2017, and entitled “Galmed Pharmaceuticals
to Present at International Liver Congress Data that Shows Aramchol
TM
has a Potential Direct Effect on Liver Fibrosis.”
This Form 6-K is incorporated by reference
into the Company's Registration Statement on Form S-8 filed with the Securities and Exchange Commission on August 11, 2015 (Registration
No. 333-206292) and its Registration Statement on Form F-3 filed with the Securities and Exchange Commission on March 31, 2015
(Registration No. 333-203133).
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
Galmed Pharmaceuticals Ltd.
|
|
|
|
Date: April 5, 2017
|
By:
|
/s/
Allen Baharaff
|
|
|
Allen Baharaff
|
|
|
President and Chief Executive Officer
|
Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
From Sep 2023 to Sep 2024